×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EQ – equillium, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EQ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
04:12 pm
eq
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates [Yahoo! Finance]
High
Report
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates [Yahoo! Finance]
11/13
04:01 pm
eq
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
High
Report
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
11/13
08:00 am
eq
Equillium to Present at the Stifel Healthcare Conference
Medium
Report
Equillium to Present at the Stifel Healthcare Conference
11/12
11:02 am
eq
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
08:00 am
eq
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
High
Report
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
11/6
11:24 am
eq
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth [Yahoo! Finance]
Low
Report
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth [Yahoo! Finance]
10/7
08:00 am
eq
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
High
Report
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
9/22
12:39 am
eq
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/15
06:23 pm
eq
Form 4 Equillium, Inc. For: Nov 14 Filed by: Keyes Jason A
Medium
Report
Form 4 Equillium, Inc. For: Nov 14 Filed by: Keyes Jason A
11/14
09:51 pm
eq
Form SC 13G/A Equillium, Inc. Filed by: Decheng Capital Management IV (Cayman), LLC
Low
Report
Form SC 13G/A Equillium, Inc. Filed by: Decheng Capital Management IV (Cayman), LLC
11/14
04:20 pm
eq
Form 144 Equillium, Inc. Filed by: Keyes Jason A
Low
Report
Form 144 Equillium, Inc. Filed by: Keyes Jason A
11/13
04:11 pm
eq
Form 10-Q Equillium, Inc. For: Sep 30
High
Report
Form 10-Q Equillium, Inc. For: Sep 30
11/13
04:06 pm
eq
Form 8-K Equillium, Inc. For: Nov 13
High
Report
Form 8-K Equillium, Inc. For: Nov 13
10/29
04:15 pm
eq
Form 4 Equillium, Inc. For: Oct 25 Filed by: Tom Penny
Low
Report
Form 4 Equillium, Inc. For: Oct 25 Filed by: Tom Penny
9/27
07:38 pm
eq
Form 4 Equillium, Inc. For: Sep 26 Filed by: Keyes Jason A
Low
Report
Form 4 Equillium, Inc. For: Sep 26 Filed by: Keyes Jason A
9/17
06:14 pm
eq
Form 4 Equillium, Inc. For: Sep 16 Filed by: Tom Penny
Neutral
Report
Form 4 Equillium, Inc. For: Sep 16 Filed by: Tom Penny
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
33.1%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
TOP News Decliners
12/31
Equillium (NYSE: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
-19.3%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: